Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
fda
life sciences
national blog main
national top stories
new york top stories
san francisco top stories
4
×
biotech
boston blog main
boston top stories
national
new york blog main
san diego blog main
san diego top stories
san francisco blog main
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe top stories
gene therapy
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
rna interference
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
akcea therapeutics
ambys medicines
amicus therapeutics
ampio pharmaceuticals
angelman syndrome
arena pharmaceuticals
What
fda
4
×
patients
4
×
drug
medicine
friday
therapy
ago
alnylam
approve
approved
aren’t
atrophy
awaits
bio
biological
cancer
crossed
daily
decades
decision
developers
discovered
drugs
eisai
evrysdi
fingers
flags
gene
green
help
higher
historic
home
imminent
incidence
intended
lights
liquid
long
lorcaserin
Language
unset
Current search:
patients
×
" san francisco top stories "
×
fda
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision